X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1867) 1867
Book Review (248) 248
Publication (84) 84
Conference Proceeding (8) 8
Book Chapter (7) 7
Magazine Article (4) 4
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1698) 1698
index medicus (1577) 1577
male (921) 921
waldenstrom macroglobulinemia - pathology (801) 801
female (741) 741
aged (740) 740
middle aged (726) 726
waldenstrom macroglobulinemia - complications (474) 474
hematology (357) 357
adult (350) 350
waldenstrom macroglobulinemia - diagnosis (330) 330
abridged index medicus (302) 302
oncology (280) 280
waldenstrom macroglobulinemia - immunology (279) 279
waldenstrom macroglobulinemia (270) 270
waldenstrom macroglobulinemia - drug therapy (246) 246
pathology (232) 232
bone marrow - pathology (228) 228
waldenstroms macroglobulinemia (227) 227
aged, 80 and over (205) 205
diagnosis, differential (193) 193
waldenstrom macroglobulinemia - genetics (167) 167
waldenstrom macroglobulinemia - blood (157) 157
biopsy (148) 148
multiple-myeloma (146) 146
immunoglobulin m - analysis (145) 145
multiple myeloma - pathology (138) 138
lymphoma (137) 137
chronic lymphocytic-leukemia (135) 135
rituximab (130) 130
waldenstrom's macroglobulinemia (128) 128
prognosis (125) 125
lymphoplasmacytic lymphoma (117) 117
animals (115) 115
lymphomas (115) 115
macroglobulinemia (112) 112
waldenstrom macroglobulinemia - therapy (108) 108
monoclonal gammopathy (96) 96
multiple myeloma (96) 96
immunoglobulin m - blood (95) 95
lymph nodes - pathology (95) 95
treatment outcome (95) 95
waldenstrom macroglobulinemia - metabolism (94) 94
b-lymphocytes - pathology (93) 93
diagnosis (93) 93
immunoglobulin m (91) 91
mutation (90) 90
immunoelectrophoresis (89) 89
waldenström's macroglobulinemia (88) 88
antineoplastic combined chemotherapy protocols - therapeutic use (81) 81
waldenström macroglobulinemia (80) 80
plasma cells - pathology (79) 79
cancer (77) 77
immunophenotyping (77) 77
immunohistochemistry (73) 73
multiple myeloma - immunology (73) 73
disease (72) 72
retrospective studies (72) 72
flow cytometry (70) 70
antineoplastic agents - therapeutic use (69) 69
old medline (69) 69
multiple myeloma - complications (68) 68
disease progression (66) 66
leukemia (66) 66
medicine, general & internal (66) 66
b-cell lymphoma (65) 65
myeloid differentiation factor 88 - genetics (64) 64
bone marrow (63) 63
clinical neurology (63) 63
lymphoma - pathology (63) 63
immunoglobulins (62) 62
mice (62) 62
microscopy, electron (62) 62
paraproteinemias - pathology (62) 62
multiple myeloma - diagnosis (61) 61
blood protein electrophoresis (60) 60
immunoglobulin m - immunology (59) 59
undetermined significance (58) 58
hematology, oncology and palliative medicine (56) 56
leukemia, lymphocytic, chronic, b-cell - pathology (56) 56
lymphoma, non-hodgkin - pathology (55) 55
therapy (55) 55
waldenstrom macroglobulinemia - etiology (55) 55
blood viscosity (54) 54
expression (53) 53
plasma cells (53) 53
risk factors (52) 52
follow-up studies (51) 51
amyloidosis - pathology (50) 50
igm monoclonal gammopathy (50) 50
syndrome (50) 50
lung - pathology (49) 49
medicine & public health (49) 49
myeloma (49) 49
amyloidosis - complications (48) 48
b-lymphocytes - immunology (48) 48
chlorambucil - therapeutic use (48) 48
immunoglobulin g - analysis (48) 48
consensus panel recommendations (47) 47
immunoglobulin m - metabolism (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1501) 1501
French (136) 136
Japanese (75) 75
German (56) 56
Spanish (40) 40
Italian (22) 22
Chinese (10) 10
Russian (7) 7
Danish (4) 4
Dutch (4) 4
Polish (4) 4
Portuguese (4) 4
Croatian (3) 3
Czech (3) 3
Norwegian (2) 2
Bulgarian (1) 1
Hungarian (1) 1
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 7, pp. 1222 - 1232
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/2015, Volume 125, Issue 15, pp. 2370 - 2380
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 19, pp. 3276 - 3282
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3830 - 3835
Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | MANTLE-CELL LYMPHOMA | IN-VITRO | ONCOLOGY | PROTEASOME INHIBITOR BORTEZOMIB | NON-HODGKINS-LYMPHOMA | PHASE-II | RELAPSED MULTIPLE-MYELOMA | CHOP-R | COOPERATIVE-ONCOLOGY-GROUP | Herpes Zoster - prevention & control | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal - adverse effects | Hematocrit | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Waldenstrom Macroglobulinemia - pathology | Waldenstrom Macroglobulinemia - drug therapy | Aged, 80 and over | Female | Boronic Acids - administration & dosage | Waldenstrom Macroglobulinemia - blood | Antibodies, Monoclonal, Murine-Derived | Bortezomib | Dexamethasone - administration & dosage | Drug Administration Schedule | Blood Viscosity - drug effects | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Bone Marrow Neoplasms - secondary | Herpes Zoster - chemically induced | Disease-Free Survival | Immunoglobulin M - blood | Platelet Count | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Aged | Bone Marrow Neoplasms - drug therapy | Index Medicus | Original Reports | Hema15 | Bios3 | Hema23
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2018, Volume 183, Issue 4, pp. 564 - 577
We present a nationwide prospective Swedish registry‐based study of Waldenström macroglobulinaemia ( WM ), that focuses on incidence and survival in relation... 
prognostic factors | lymphoproliferative disease | Waldenström macroglobulinaemia | therapy | Waldenström macroglobulinaemia survival | CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | ONCOLOGY-GROUP | RANDOMIZED-TRIAL | Waldenstrom macroglobulinaemia survival | CELL LYMPHOMAS | Waldenstrom macroglobulinaemia | LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROMS MACROGLOBULINEMIA | NON-HODGKIN-LYMPHOMA | REAL-WORLD DATA | POOLED ANALYSIS | SCORING SYSTEM | HEMATOLOGY | Waldenstrom Macroglobulinemia - blood | Prospective Studies | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Risk Factors | Male | Survival Rate | Sweden - epidemiology | Incidence | Waldenstrom Macroglobulinemia - pathology | Disease-Free Survival | Sex Factors | Adult | Female | Registries | Aged | Retrospective Studies | Waldenstrom Macroglobulinemia - mortality | Medical records | Hemoglobin | Care and treatment | Lymphomas | Prognosis | Analysis | Immunoglobulin M | Therapy | Rituximab | Lactate dehydrogenase | Lymphoma | Survival | Patients | L-Lactate dehydrogenase | Medical prognosis | Diagnostic systems | Lactic acid | Diagnosis | Age | Macroglobulinemia | Index Medicus | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | ldenstrom macroglobulinaemia survival | Klinisk medicin
Journal Article